Hilary Blacklock

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

James R. Berenson, Alan Lichtenstein, Lester Porter et al. · New England Journal of Medicine · 1996 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +16

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael et al. · The Lancet · 2021 · 380 citations

Medicine, Pharmacology, Pharmacotherapy +12

DEPLETION OF T LYMPHOCYTES IN DONOR MARROW PREVENTS SIGNIFICANT GRAFT-VERSUS-HOST DISEASE IN MATCHED ALLOGENEIC LEUKAEMIC MARROW TRANSPLANT RECIPIENTS

H. G. Prentice, George Janossy, L. Price-Jones et al. · The Lancet · 1984 · 359 citations

Medicine, Hematology, Immunology +10

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 253 citations · Full text

Medicine, Oncology, Pharmacology +12

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

Meletios Α. Dimopoulos, David S. Siegel, Sagar Lonial et al. · The Lancet Oncology · 2013 · 227 citations

Medicine, Pharmacology, Pharmacotherapy +14